BioNxt Solutions Inc.
15.8.2024 22:04:41 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Promotes Kevin Gee to Vice President of Pro Product Development - FLEX28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Chervon promotes Kevin Gee to Vice President of Pro Product Development - FLEX, effective Monday, September 28, 2026, reporting to CEO Joe Galli. Kevin Gee joined Chervon after a 15-year international career in the Milwaukee Pro Power Tool business. He started his career at TTI in 2011 as a Field Sales Store Representative in Toronto, Ontario. He moved through several Milwaukee marketing positions in Canada and was then promoted to a marketing position with Milwaukee based in Hong Kong in 2013. He then rose to the position of Group Marketing Manager in Milwaukee Asia in 2016. In 2017, Kevin was moved to Milwaukee U.S.A. and advanced through a series of Milwaukee product management positions from 2017 to 2023. His final position was Director of Product Management for Milwaukee Pro Tools from 2021 to 2023. Most recently, Kevin held the position of Chief Revenue and Marketing Officer for Guardian Safety Equipment before joining Cherv
Chervon Names Trevor Bithrey Vice President Pro End User Marketing and Research - Canada28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Trevor Bithrey joins Chervon as Vice President, Pro End User Marketing and Research - Canada, effective Monday, September 28, reporting to CEO Joe Galli. Bithrey joins Chervon with over 25 years of professional power tools experience. He has excelled in his increasingly responsible positions in building both the DeWalt Canada business and the Milwaukee Canada business. He brings an impressive and diverse skillset in account management, end user marketing, aftersales service and end user research. He also has experience building and leading exceptional teams in Canada. Bithrey will also be part of the newly formed Chervon Global End User Research and Jobsite Marketing team, reporting directly to CEO Joe Galli. Bithrey's career started at DeWalt Canada where he held a series of sales and product management positions from 2000 to 2007. He then moved to Milwaukee Canada from 2007 until 2023 where he advanced through key leadership rol
Fermi Selects NAES to Operate and Maintain Its Natural Gas Turbine Fleet28.9.2026 13:00:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 28, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today an operations and maintenance (O&M) agreement with NAES Corporation ("NAES"), the largest independent operator of power plants in the United States. Under the agreement, NAES will run and maintain Fermi's natural gas turbine fleet at its Project Matador private-power campus in Carson County, Texas. "This agreement puts a proven and experienced operator in place that has been running power plants for more than 45 years," said Lee McIntire, Fermi Chief Executive Officer. "Our first customer is signed, our turbines are secured, and our EPC partners are on board. Now, with NAES, we're adding an operating partner with operations and maintenance depth, skilled crews, and proven management systems before the first natural-gas generation units come online. That protects uptime for the customers who are counting on us for quality and rel
Camino Receives Environmental Approval for Significant Exploration Expansion at the Costa de Cobre Copper Project in Peru28.9.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its Peruvian subsidiary, a 65/35 joint venture between Camino and Nittetsu Mining Co., Ltd. ("Nittetsu"), has received approval from Peru's Ministry of Energy and Mines ("MINEM") for the Second Modification of the Semi-Detailed Environmental Impact Assessment ("Second MEIA-sd") for its Costa de Cobre Project (formerly known and referred to in the permit as Los Chapitos), along the coastline in southern Peru. The approval represents a major milestone for Costa de Cobre, increasing the effective exploration area by approximately 94%, from 6,012.50 hectares to 11,671.90 hectares, and expanding the environmental framework to support a total of 280 drill platforms and up to 611,840 metres of drilling capacity, covering major portions of the three copper fault trends crossing Camino's claims: Diva trend; La Estancia trend; and the
Case IQ Launches Quantum Approvals & Disclosures So Compliance Teams Find Risk Earlier28.9.2026 10:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / September 28, 2026 / Case IQ, a leading provider of compliance and risk management solutions, today announced the launch of Quantum Approvals & Disclosures, a native AI-powered solution designed to help organisations identify risk earlier, reduce manual effort, and make more consistent, defensible compliance decisions. In addition to the embedded governed AI capabilities that support employees and compliance reviewers, the solution launches with two ready-to-use AI agents, Submission Support and Risk Spotlight. Employees receive intelligent guidance that helps them submit more complete and accurate information, while compliance teams gain the context needed to prioritise higher-risk activity and proactively engage before potential issues escalate. The solution supports complex approval and disclosure programmes spanning conflicts of interest, gifts and hospitality, donations and sponsorships, and other risk areas. By bringing submissions, reviews, decisio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom